- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02486510
Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication (CHEMOMAR)
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase temprana 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Madrid, España, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, España, 28046
- Hospital Universitario La Paz
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients who give written consent to participate in the study
- Age between 18 and 65 years old, included.
- Chronic HIV-1 Demonstration of R5 viral tropism (use of CCR5 coreceptors) by genotyping in plasma samples stored
- Patients that are to be treated with intensive chemotherapy for non Hodgkin lymphoma With or without stable antiretroviral therapy
- Patients that are able to understand the purpose of the study and be available for scheduled appointments.
- Both in the case of female and male patients, the patient agrees to use a double barrier method of contraception from the moment of signing the informed consent until 3 months after the end of their participation in the study.
Exclusion Criteria:
- To have planned antiretroviral treatment interruption during the participation in the study
- Hypersensitivity to products used in this study
- To be involved in another clinical trial or received an investigational drug within 3 months prior to the study initiation
- To have contraindications or limitations to perform leukapheresis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Sin intervención: Group 1 (Control)
Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it. Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo) |
|
Experimental: Group 2 (Treatment)
Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc. Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc. |
Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery. Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
number of resting memory CD4+ T cells latently infected with replicative HIV-1, expressed as IUPM
Periodo de tiempo: Same as chemotherapy treatment (expected average of 6 months)
|
Primary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels
|
Same as chemotherapy treatment (expected average of 6 months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proviral DNA (copies/million cells)
Periodo de tiempo: Same as chemotherapy treatment (expected average of 6 months)
|
Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels
|
Same as chemotherapy treatment (expected average of 6 months)
|
Effector T cells producing HIV-1 specific gamma interferon (cells/mm3)
Periodo de tiempo: Same as chemotherapy treatment (expected average of 6 months)
|
Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels
|
Same as chemotherapy treatment (expected average of 6 months)
|
Levels of HIV-1 antibodies
Periodo de tiempo: Same as chemotherapy treatment (expected average of 6 months)
|
Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels
|
Same as chemotherapy treatment (expected average of 6 months)
|
Percentage of CD4+ and CD8+ cells with immune activation markers
Periodo de tiempo: Same as chemotherapy treatment (expected average of 6 months)
|
Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels
|
Same as chemotherapy treatment (expected average of 6 months)
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7. doi: 10.1073/pnas.94.24.13193.
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997 Nov 14;278(5341):1295-300. doi: 10.1126/science.278.5341.1295.
- Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004 Sep 15;190(6):1046-54. doi: 10.1086/422848. Epub 2004 Aug 17.
- Moreno S, Mocroft A, Monforte Ad. Medical and societal consequences of late presentation. Antivir Ther. 2010;15 Suppl 1:9-15. doi: 10.3851/IMP1523.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CHEMOMAR
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infección por VIH-1
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Oxford Brookes UniversityUniversity of OxfordTerminadoActividad física | Salud Mental Bienestar 1 | Función Cognitiva 1, Social | Academic Attainment | Fitness TestingReino Unido
-
Merck Sharp & Dohme LLCReclutamientoCáncer de pulmón de células no pequeñas | Tumores sólidos | Muerte celular programada-1 (PD1, PD-1) | Ligando 1 de muerte celular programada 1 (PDL1, PD-L1) | Ligando 2 de muerte celular programada 1 (PDL2, PD-L2)Japón
-
SanionaTerminado
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionTerminado
-
Calliditas Therapeutics ABTerminado
-
JKT Biopharma Co., Ltd.Reclutamiento
-
Graviton Bioscience CorporationTerminado
-
Rambam Health Care CampusIsrael Science FoundationTerminado
-
Alvotech Swiss AGTerminado
Ensayos clínicos sobre Maraviroc
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoTrasplante de células madre hematopoyéticas | Enfermedad de injerto contra huésped
-
ViiV HealthcarePfizerYa no está disponible
-
Kirby InstituteTerminadoEnfermedad cardiovascularArgentina, Australia, Alemania, Tailandia
-
International Partnership for Microbicides, Inc.Retirado
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Terminado
-
International Partnership for Microbicides, Inc.TerminadoInfecciones por VIHEstados Unidos
-
University Of PerugiaTerminadoInflamación | Aterosclerosis | Factor de riesgo cardiovascular | Infección por VIH con otras condicionesItalia
-
Emory UniversityTerminado
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCTerminadoInfecciones por VIHEstados Unidos
-
National Institute of Allergy and Infectious Diseases...TerminadoInfecciones por VIHEstados Unidos, Puerto Rico, Tailandia, Sudáfrica, Brasil